In patients with localized ER+/HER2- cancer associated with bulky node involvement after initial surgery, or treated with neoadjuvant chemotherapy, BRCA1/2 status genotyping should be implemented, so olaparib can be prescribed as an adjuvant treatment in patients carrying BRCA1/2 PV. The gene discussed is ERBB2; the disease is cancer.